Plenty of money changed hands in pharmaceutical M&A terms in August, albeit big pharma companies were largely not involved.
Of the seven firms that announced deals during the month, only one—Otsuka Pharmaceuticals(TYO: 4578)—is classed as a top 50 pharma company.
But a number of deals did surface, including the merger of US AI-enabled biotech Recursion (Nasdaq: RXRX) and UK-based Exscientia (Nasdaq: EXAI), in an all-stock transaction reportedly valued at $688 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze